RESOLUTION OF DIABETIC VASCULAR INFLAMMATION: ROLE OF LIPID MEDIATORS PROJ5

糖尿病血管炎症的解决：脂质介质的作用 PROJ5

• 批准号: 8360418
• 负责人: Matthew R Spite
• 金额: $ 18.68万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360418
• 关键词: Acute; Affect; Anabolism; Blood Vessels; Chronic; Diabetes Mellitus; Diabetic mouse; Endothelial Cells; Fatty Acids; Functional disorder; Funding; Glucose; Grant; Hyperglycemia; Hyperinsulinism; Infiltration; Inflammation; Inflammatory; Injection of therapeutic agent; Insulin-Dependent Diabetes Mellitus; Leukocytes; Lipoxins; Measures; Mediator of activation protein; Modeling; Mus; National Center for Research Resources; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathway interactions; Peritonitis; Phase; Principal Investigator; Research; Research Design; Research Infrastructure; Resolution; Resources; Role; Signal Pathway; Source; Streptozocin; Testing; Time; United States National Institutes of Health; cost; db/db mouse; design; diabetic; indexing; intravital microscopy; lipid mediator; liquid chromatography mass spectrometry; microbial; non-diabetic; novel; prevent; restoration; type I and type II diabetes; vascular inflammation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Project 5: Resolution of diabetic vascular inflammation: Role of lipid mediators The overall aim of this project is to develop a better understanding of the mechanisms that support and sustain chronic low-grade vascular inflammation in diabetes and whether the resolution phase of inflammation could be stimulated to prevent vascular dysfunction in diabetes. Our hypothesis is that chronic vascular inflammation during diabetes could be attributed, in part, to a loss in endogenous counter-regulatory lipid mediator pathways that promote the resolution of inflammation. It follows that restoration of these deficits with synthetic pro-resolving lipid mediators, such as the lipoxins and resolvins, could facilitate the resolution of vascular inflammation associated with long-term diabetes. The following specific aims were designed to test this novel hypothesis: 1. Examine diabetic changes in the resolution of acute inflammation. For this, we will measure the intensity and duration of leukocyte infiltration in a murine model of microbial peritonitis in which we have defined specific resolution indices. The time course of inflammation will be studied in non-diabetic mice and in murine models of both type 1 and type 2 diabetes. Type 1 diabetes will be established by streptozotocin injections and for studying type 2 diabetes, db/db mice will be used. Comparisons between these models will help in assessing the contribution of hyperglycemia and hyperinsulinemia to diabetic changes in the resolution of inflammation and in understanding the mechanism by which diabetes affects the resolution of inflammation; 2. Assess the contribution of altered pro-resolution lipid mediator biosynthesis to diabetic changes in resolution. To understand how diabetes affects resolution, we will identify changes in lipid mediator biosynthesis during peritonitis using targeted liquid chromatography/mass spectrometry. We will determine which lipid mediator pathways (pro-inflammatory vs. pro-resolution) are affected during the time course of peritonitis in models of both type 1 and type 2 diabetes. Moreover, to elucidate the mechanisms by which diabetes affects pro-resolution lipid mediator biosynthesis, we will measure their biosynthetic intermediates and determine how they are affected by diabetes; and 3. Determine whether treatment with pro-resolution lipid mediators restores diabetic changes in resolution. We will determine how treatment with exogenous lipoxins and resolvins affects the resolution of peritonitis in non-diabetic and diabetic mice. To delineate the mechanisms by which these mediators affect inflammation, we will examine their effects on leukocyte:endothelial interactions by intravital microscopy. To elcuidate the cellular mechanisms by which pro-resolution lipid mediators counter-act diabetic vascular inflammation, we will examine how lipoxins and resolvins affect high glucose and high fatty acid-induced signaling pathways in microvascular endothelial cells.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 项目5：糖尿病血管炎症的分辨率：脂质介质的作用 该项目的总体目的是更好地了解糖尿病中支持和维持慢性低度血管炎症的机制，以及是否可以刺激炎症的分辨率阶段以防止糖尿病的血管功能障碍。 我们的假设是，糖尿病期间的慢性血管炎症可能部分归因于内源性反调节性脂质介质途径的丧失，从而促进炎症的分辨率。 因此，与合成的促脂质介质（如脂毒素和溶质蛋白）一起恢复了这些缺陷，可以促进与长期糖尿病相关的血管炎症的分辨率。以下特定目标旨在检验这一新假设： 1。检查急性炎症分辨率的糖尿病变化。 为此，我们将测量白细胞浸润的强度和持续时间在微生物腹膜炎的鼠模型中，其中我们定义了特定的分辨率指数。炎症的时间过程将在非糖尿病小鼠和1型和2型糖尿病的鼠模型中进行研究。 1型糖尿病将通过链霉菌素注射和研究2型糖尿病来建立，将使用DB/DB小鼠。 这些模型之间的比较将有助于评估高血糖和高胰岛素血症对炎症解决方案的糖尿病变化以及理解糖尿病影响炎症解决的机制的贡献； 2。评估改变促脂质脂质介质生物合成对糖尿病变化的分辨率变化的贡献。 为了了解糖尿病如何影响分辨率，我们将使用靶向的液相色谱/质谱法确定腹膜炎期间脂质介质生物合成的变化。 我们将确定在1型和2型糖尿病模型的腹膜炎期间，在腹膜炎的时间内影响了哪些脂质介质途径（促炎与促分解）。 此外，为了阐明糖尿病影响促脂质脂质介质生物合成的机制，我们将测量它们的生物合成中间体并确定它们如何受糖尿病的影响；和 3。确定促分辨率脂质介质治疗是否会恢复分辨率的糖尿病变化。我们将确定外源性脂毒素和溶质蛋白的治疗如何影响非糖尿病和糖尿病小鼠的腹膜炎的分辨率。为了描述这些介体影响炎症的机制，我们将检查它们对白细胞的影响：通过浸润显微镜检查的内皮相互作用。为了促进促脂质脂质介质对抗糖尿病血管炎症的细胞机制，我们将研究脂毒素和溶质蛋白如何影响高葡萄糖和高脂肪酸诱导的微血管内皮细胞中的信号途径。